Lead Research Scientist
Pam Katzen Burrows, M.S., joined The Biostatistics Center in 1991 as coordinator for the Angiotensin Converting Enzyme Inhibition (ACEi) with Captopril in Diabetic Nephropathy and Routine Antenatal Diagnostic Imaging with Ultrasound (RADIUS) studies, which were funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and National Institute of Child Health and Development (NICHD) respectively. She was the biostatistician/project coordinator and the coordinating center Principal Investigator for the Medical Therapy of Prostatic Symptoms (MTOPS) study, funded by NIDDK. She has been the biostatistician for the Management Of Myelomeningocele (MOMS) since 2002, and starting in 2011, the Follow-up to the Management Of Myelomeningocele (MOMS2), both funded by NICHD. She also is currently one of the Principal Investigators for the Randomized Trial To Study Tamsulosin For Urolithiasis In The Emergency Department (STONE) project, funded by the NIDDK and the biostatistician on the SNP-based Microdeletion and Aneuploidy RegisTry (SMART) and the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Pam is also a member of an External Experts Panel (EEP) for an NIDDK Network. .
Current BSC Projects
Maternal-Fetal Medicine Units Network (MFMU)
Position Type: Research Investigators